Elekta Announces Monaco 5.0 – Comprehensive Radiation Treatment Planning Capabilities Brought Together in One System

New workflow and system architecture designed to improve processing speed,
enhance planning productivity
ATLANTA, Sept. 21 /PRNewswire/ – Elekta today announced Monaco® 5.0, which
consolidates support for all of the most clinically useful delivery techniques
in a single treatment planning system, and features refinements to planning
speed and precision.

“This latest Monaco release brings together the best capabilities of Elekta’s
treatment planning portfolio into a single planning system to achieve a greater
level of convenience and clinical versatility for the radiation oncology team,”
says Todd Powell, Executive Vice President of Elekta Software. “And, with a new
system architecture, sophisticated treatment plans can now be developed with
speeds often not attainable with previous planning systems.”

Uniquely relying on an advanced Monte Carlo dose engine – considered the gold
standard for calculating delivered radiation – Monaco is now a truly
comprehensive treatment planning system, supporting the full breadth of
radiation therapy techniques, including VMAT, IMRT, and 3D conformal radiation
therapy. The system is exceptionally equipped for advanced stereotactic
therapies, such as SRS and SRT, with added planning support for specialized beam
shaping devices, including circular cones.

“Developing treatment plans can be a resource-intensive task that limits a
clinic’s productivity and throughput,” says Richard Stark, Senior Vice President
of Elekta Software. “With a reinvented workflow and user interface, Monaco 5.0
is designed to simplify and accelerate the radiotherapy planning process.
Combining these capabilities with a new system architecture based on CPU
[central processor unit] and GPU-based [graphics processor unit] technology,
Monaco sets a new standard in accuracy and speed.”

Learn more at www.elekta.com/Monaco.

3D conformal radiation therapy, stereotactic cone and GPU-based architecture are
pending FDA 510(k) clearance.

# # #

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: ET: Eastern Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, e-mail: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 15:00 CET on September 21, 2013.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both healthcare providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,500 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.